The company has taken advantage of the synergistic effect of biologics and diagnostic reagents business in the field of precision medicine, actively explored and laid out the “patient-centered” personalized medical field business, and initially formed the industrial chain layout of precision medicine.
The Group's precision medical sector has now innovated its incentive model, optimized its business structure, and adjusted the equity of Livzon Shengmei. Livzon Monoclonal Antibody has been restructured and financed.
By the end of 2018, 3 in vitro diagnostic reagents had obtained registration certificates, 6 were in the clinical stage, and 2 were in the registration stage. Two instruments and equipments had been registered and two were in the registration stage.